Neurocrine Biosciences, Inc. will participate at the Stifel 2025 Virtual CNS Forum at 1:30 p.m. Eastern Time on Tuesday, March 18, 2025. Chief Executive Officer Kyle Gano and Chief Medical Officer ...

Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts ("ADRs") of GSK plc (NYSE:GSK) between February 5, 2020 and August 14, 2022, both dates inclusive ...

To join the GSK class action, go to https://rosenlegal.com/submit-form/?case_id=34609 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class ...

Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...

GlaxoSmithKline's head of oncology Axel Hoos has resigned from the company, and will take up a new role as chief executive of US biotech Scorpion Therapeutics. Hoos is leaving GSK after nine ...

However, the result has cemented GSK's view that dostarlimab can become the "backbone" of its immuno-oncology R&D programmes, according to the company's head of oncology development, Hesham Abdullah.

One of the most highly anticipated FDA decisions this month is for Alnylam Pharmaceuticals, which is seeking to expand the ...

DelveInsight's "TAGRISSO Market Size, Forecast, and Market Insight Report" highlights the details around TAGRISSO, a kinase ...

DelveInsight's "ROZLYTREK Market Size, Forecast, and Market Insight Report" highlights the details around ROZLYTREK, an ...

TAGRISSO has become a standard treatment due to its strong efficacy in both first-line and adjuvant settings. The growing prevalence of EGFR mutations, a rise in lung cancer diagnoses, and broader ...

It is also using some of the same knowhow to develop cancer drugs ... larger companies looking to commercialise AMR medicines is GlaxoSmithKline, which has completed three phase-II trials for ...